Stay updated on Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Sign up to get notified when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.

Latest updates to the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedRevision tag on the page updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision label updated from v3.4.1 to v3.4.2 in the page footer. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision: v3.4.1 is now shown on the page, replacing the previous v3.4.0. This is a minor site update and does not modify any study details or eligibility criteria.SummaryDifference0.0%

- Check74 days agoChange DetectedUI text updates: Show glossary and Hide glossary options have been added, QC-related labels updated to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', and the 'No FEAR Act Data' wording adjusted. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check81 days agoChange DetectedRevision: v3.3.4 has been added to the page. The previous Revision: v3.3.3 has been removed.SummaryDifference0.1%

Stay in the know with updates to Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab
Enter your email address, and we'll notify you when there's something new on the Lung Squamous Carcinoma Combo Trial: Afatinib + Pembrolizumab page.